Disease relevance of C06870

• Each patient had a long history of Parkinson's disease treated with a carbidopa-levodopa combination [1].
• Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma [2].
• OBJECTIVE: To describe the clinical and molecular genetic analysis of a large family of northern Chinese descent with a mutation at the SCA2 locus causing carbidopa-levodopa-responsive parkinsonism [3].
• Adjunctive treatment with controlled-release MK-458 elicited less choreiform dyskinesias than either pergolide adjunctive therapy or therapy with carbidopa-levodopa alone; this finding suggests that D-1 receptor stimulation contributes to the elicitation of medication-induced chorea [4].
• Carbidopa-levodopa therapy for movement disorders [5].

Psychiatry related information on C06870

• Entacapone increased the duration of action of carbidopa-levodopa and resulted in longer periods of symptomatic relief in a patient with restless legs syndrome [6].
• Apraxia of lid opening: dose-dependent response to carbidopa-levodopa [7].
• Clinicians should be aware of adverse reactions, such as AOL, in patients taking carbidopa-levodopa who have dementia of the Lewy body type [7].
• Carbidopa-levodopa-induced recrudescence of premorbid tic disorder in remission [8].
• RESULTS: Increased levels of fatigue were associated with decreased levels of leisure physical activity, lower frequency of vigorous physical activity, less time spent moving about performing daily tasks each day, lower diastolic blood pressure and VO(2max), longer Up and Go performance time, and carbidopa-levodopa (CL) use [9].

High impact information on C06870

• This latter strategy led to the development of sustained-release carbidopa-levodopa, which was compared with immediate-release carbidopa-levodopa in the CR Five-Year International Response Fluctuation Study (FIRST), a 5-year multicenter study of early, levodopa-naive PD patients [10].
• Dystonia was typically least severe in the morning, increased as the day continued, and markedly improved with low doses of carbidopa-levodopa [11].
• Twenty parkinsonian patients (Hoehn and Yahr scale, I through III) were treated with controlled-release carbidopa-levodopa (CR-2 or CR-3) and standard carbidopa-levodopa (Sinemet, 25 mg/100 mg) in a double-blind, crossover pharmacokinetic and clinical efficacy study [12].
• Twenty-one patients with Parkinson's disease were studied because their low maintenance dosages of carbidopa-levodopa in the customary ratio of 1:10 provided less than the daily 75 mg of carbidopa believed necessary to achieve full inhibition of extracerebral dopa decarboxylation [13].
• We conclude that a multidisciplinary team approach and in selected cases, the use of carbidopa-levodopa are valid methods for the rehabilitation of patients with Hallervorden-Spatz Syndrome [14].

Chemical compound and disease context of C06870

• We report here the single and combined antitumor activity on B16 melanoma in female C57BL/6 X DBA/2F1 mice bearing s.c. tumors of sodium ascorbate, carbidopa-levodopa methyl ester, and dietary phenylalanine and tyrosine deficiency [2].
• 4-Propyl-9-hydroxynaphthoxazine, or MK-458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained-release form, was studied as adjunctive therapy with carbidopa-levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations [15].
• We report a 65-year-old male parkinsonian patient who developed dominantly unilateral choreic movements over his right-side extremities after a daily dosage of up to 1,000 mg of carbidopa-levodopa (carbidopa 200 mg, levodopa 800 mg) for 12 years [16].

Biological context of C06870

• From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations [17].

Anatomical context of C06870

• After informed consent, 70 subjects took a tablet of carbidopa-levodopa association (Sinemet or Sinemet-CR) 0.5, 1, 2, 4, 8, 12 h before blood and lumbar cerebrospinal fluid collection [18].

Gene context of C06870

• Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report [19].
• The Up and Go Test, Leisure Activity Score, CL use, VO(2max), and diastolic blood pressure were the best predictor variables of fatigue [9].

Analytical, diagnostic and therapeutic context of C06870

• Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy [20].
• We administered pergolide to patients with suboptimal control of Parkinson's disease who had a short-duration response to carbidopa-levodopa in a 6-month, double-blind study [21].
• Levodopa is typically introduced in the form of carbidopa-levodopa, with upward dosage titration weekly until symptoms improve [22].

References